novo nordisk oral semaglutide brand name The U.S. Food and Drug Administration approved Nordisk's (Wegovy) as the first GLP-1 pill for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo Obesity | Novo Nordisk U.S.
Pay in 4 interest-free payments of $6.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24



:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)




















